---
document_datetime: 2026-01-06 10:59:22
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tyverb-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tyverb-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5293771
conversion_datetime: 2026-01-10 11:27:57.272785
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tyverb

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | A. ADMINISTRATIVE CHANGES - A.7 | 05/01/2026                          |                                             | Annex II and                     |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000320526                        | Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            | PL          |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| Variation type IA_IN / EMA/VR/0000291894 | This was an application for a group of variations. A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.a The activities for which the manufacturer/importer is responsible include batch release - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted | 21/08/2025 | Annex II PL |

<div style=\"page-break-after: always\"></div>

| PSUR / EMA/PSUR/0000282260   | - -   | Maintenance   |
|------------------------------|-------|---------------|